REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer-Reference-Cited by-同舟云学术

REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer

Published:2021-05 Issue:2 Volume:161 Page:374-381
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Sjoquist Katrin M.,Espinoza David,Mileshkin Linda,Ananda Sumitra,Shannon Catherine,Yip Sonia,Goh Jeffrey,Bowtell David,Harrison Michelle,Friedlander Michael L.

Funder

Cancer Australia

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference32 articles.

1. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG oncology/GOG study;Ferriss;Gynecol. Oncol.,2015

2. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?;Kobold;Oncologist.,2009

3. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer;Suidan;Expert Rev. Qua. Life Cancer Care,2016

4. Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis;Hilal;J.,2017

5. Accumulation of selected carotenoids, alpha -tocopherol and retinol in human ovarian carcinoma Ascitic fluid;Schweigert;Ann. Nutr. Metab.,2004

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study;Molecular Therapy;2024-06

2. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial;Translational Oncology;2024-05

3. Malignant ascites: Current therapy options and treatment prospects;Cancer Treatment Reviews;2023-12

4. Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review;Pharmaceutics;2023-06-06

5. Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels;Journal of Obstetrics and Gynaecology;2023-05-15